Unknown

Dataset Information

0

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.


ABSTRACT: The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.

SUBMITTER: Alperovich A 

PROVIDER: S-EPMC5042201 | biostudies-literature | 2016 Jan-Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Alperovich Anna A   Younes Anas A  

Cancer journal (Sudbury, Mass.) 20160101 1


The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this rev  ...[more]

Similar Datasets

| S-EPMC7102329 | biostudies-literature
| S-EPMC4196794 | biostudies-literature
| S-EPMC3744990 | biostudies-literature
| S-EPMC3873074 | biostudies-other
| S-EPMC4418463 | biostudies-literature
| S-EPMC3959807 | biostudies-literature
| S-EPMC6910100 | biostudies-literature
| S-EPMC6130098 | biostudies-literature
| S-EPMC7549381 | biostudies-literature
| S-EPMC7056527 | biostudies-literature